US Patent Office Grants the 100th Patent to Immatics Underpinning the Company’s Leading Role in the Field of Innovative Immunotherapies
03.01.2019 US Patent Office Grants the 100th Patent to Immatics Underpinning the Company’s Leading Role in the Field of Innovative Immunotherapies
Immatics, a leading company in the field of cancer immunotherapy, today announced that the United States Patent and Trademark Office has issued the 100th patent to Immatics.
This is a significant achievement for the Company and demonstrates the breadth of Immatics’ innovation power and the quality of its science. Immatics’ strong patent portfolio enables the Company to develop its pipeline of cancer immunotherapies, to protect Immatics’ innovations and to safeguard the Company’s technology investments.
Immatics’ 100th patent (US Patent No 10,143,731) is directed against a peptide target discovered using the Company’s XPRESIDENT® technology. The peptides identified by XPRESIDENT® are presented by human leucocyte antigen (HLA) receptors on the surface of cells and are central to developing a range of novel powerful immunotherapies.
“Since its inception, Immatics has put a key focus on the development of its Intellectual Property estate, in order to protect our technology innovations in this highly competitive field”, said Dr. Rainer Kramer, CBO of Immatics. “Being awarded the 100th issued US patent in the Life Science industry is fantastic, proving that our inventions move Immatics further to the forefront of the highly competitive field of Immunotherapy development.”
Immatics’ patenting strategy ensures broad protection of the Company’s products, technologies and methods while still meeting the patentability requirements in the USA in a fast-paced environment.
Dr Nikola Wiegeler
Immatics Biotechnologies GmbH
+49 7071 5397-0
media [at] immatics.com